AbCellera Biologics Inc. (ABCL) News
Track canonical SquawkNews coverage tagged to ABCL, AbCellera Biologics Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 13 indexed stories across 9 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
AbCellera Biologics Price Target Announced at $13.00/Share by Goldman Sachs
Ratings actions from Benzinga
NEWS | Sep 24, 2026, 12:12 PM UTC
L
AbCellera to present at Cantor Global Healthcare Conference Sept. 9, 2026
AbCellera said it will present at the Cantor Global Healthcare Conference on September 9, 2026. A live audio webcast and later replay will be available via a link posted on its Investor Relations website.
EQUITY | Sep 02, 2026, 08:05 PM UTC
L
AbCellera rises as FDA approves Jazz Ziihera regimens
AbCellera Biologics shares trade higher on Tuesday as investors react to FDA approval of Jazz Pharmaceuticals’ two Ziihera-containing first-line regimens, with no company-specific catalyst supplied.
GEOPOLITICS | Aug 25, 2026, 06:38 PM UTC
L
AbCellera director Montalbano files Form 4P showing 10,000 shares bought
AbCellera Biologics Inc. director John S. P. Montalbano files a Form 4P reporting a 10,000-share transaction at $11.03 for $110,300.
REGULATION | Aug 18, 2026, 06:46 PM UTC
L
AbCellera CFO AndrewP Booth files Form 4
AbCellera Biologics Inc. reports a Form 4P filing by Chief Financial Officer AndrewP Booth showing 37,200 shares reported at $10.32 for $383,904.
REGULATION | Aug 14, 2026, 04:16 PM UTC
M
ABCL prices $200M offering at $9.75 per share
ABCL priced a $200M offering at $9.75 per share, according to TradeXchange Newsdesk.
EQUITY | Aug 13, 2026, 10:02 AM UTC
M
Multiple Companies Announce Public Offerings
Several companies announce public offerings and private placements of various securities
EQUITY | Aug 12, 2026, 09:25 AM UTC
M
ABCL Launches $200M Common Stock Offering
ABCL is offering $200M in common stock
EQUITY | Aug 11, 2026, 08:03 PM UTC
L
AbCellera Biologics Commences Underwritten Public Offering Of $200M Of Its Common Shares
AbCellera Biologics Inc. (NASDAQ: ABCL ) ("AbCellera") today announced that it has commenced an underwritten public offering of $200.0 million of its common shares and, in lieu of common shares to certain investors, pre-
EQUITY | Aug 11, 2026, 08:03 PM UTC
M
ABCL Proposes Public Offering
ABCL announces proposed public offering of common stock and pre-funded warrants
EQUITY | Aug 11, 2026, 08:03 PM UTC
M
AbCellera Proposes Public Offering
AbCellera announces proposed public offering of common stock and pre-funded warrants
EQUITY | Aug 11, 2026, 08:01 PM UTC
L
Truist Securities Maintains Buy on AbCellera Biologics, Raises Price Target to $30
Truist Securities analyst Robyn Kamaus maintains AbCellera Biologics (NASDAQ: ABCL ) with a Buy and raises the price target from $12 to $30.
EQUITY | Aug 11, 2026, 05:30 PM UTC
H
AbCellera Biologics call volume above normal and directionally bullish
Bullish option flow detected in AbCellera Biologics with 3,839 calls trading, 1.1x expected, and implied vol increasing over 2 points to 114.14%. Jul-26 7 calls and Jul-26 9 calls are the most active options, with total
EARNINGS | Jul 09, 2026, 04:05 PM UTC